Northern Trust
BBIO icon

Northern Trust’s BridgeBio Pharma BBIO Stock Holding History

Northern Trust’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71.5M Sell
959,513
-444,129
-32% -$31.1M 0.01% 992
2026
Q1 		$104M Buy
1,403,642
+56,888
+4% +$4.12M 0.01% 719
2025
Q4 		$103M Sell
1,346,754
-55,655
-4% -$3.65M 0.01% 728
2025
Q3 		$72.8M Buy
1,402,409
+38,726
+3% +$1.89M 0.01% 896
2025
Q2 		$58.9M Buy
1,363,683
+76,836
+6% +$2.79M 0.01% 995
2025
Q1 		$44.5M Sell
1,286,847
-36,411
-3% -$1.23M 0.01% 1152
2024
Q4 		$36.3M Buy
1,323,258
+43,955
+3% +$1.14M 0.01% 1320
2024
Q3 		$32.6M Buy
1,279,303
+150,284
+13% +$3.95M 0.01% 1312
2024
Q2 		$28.6M Sell
1,129,019
-190
-0% -$5.2K ﹤0.01% 1339
2024
Q1 		$34.9M Sell
1,129,209
-25,763
-2% -$876K 0.01% 1236
2023
Q4 		$46.6M Buy
1,154,972
+1,057
+0.1% +$31.7K 0.01% 1057
2023
Q3 		$30.4M Buy
1,153,915
+24,643
+2% +$699K 0.01% 1268
2023
Q2 		$19.4M Buy
1,129,272
+171,915
+18% +$2.59M ﹤0.01% 1601
2023
Q1 		$15.9M Buy
957,357
+16,189
+2% +$189K ﹤0.01% 1706
2022
Q4 		$7.17M Buy
941,168
+5,130
+0.5% +$49.1K ﹤0.01% 2235
2022
Q3 		$9.3M Sell
936,038
-30,513
-3% -$317K ﹤0.01% 2026
2022
Q2 		$8.78M Sell
966,551
-30,739
-3% -$257K ﹤0.01% 2124
2022
Q1 		$10.1M Sell
997,290
-14,478
-1% -$149K ﹤0.01% 2141
2021
Q4 		$16.9M Sell
1,011,768
-103,631
-9% -$4.38M ﹤0.01% 1897
2021
Q3 		$52.3M Buy
1,115,399
+37,336
+3% +$2M 0.01% 1042
2021
Q2 		$65.7M Buy
1,078,063
+49,053
+5% +$2.8M 0.01% 923
2021
Q1 		$63.4M Buy
1,029,010
+196,174
+24% +$12.8M 0.01% 936
2020
Q4 		$59.2M Sell
832,836
-19,704
-2% -$951K 0.01% 942
2020
Q3 		$32M Buy
852,540
+62,103
+8% +$1.95M 0.01% 1249
2020
Q2 		$25.8M Buy
790,437
+8,455
+1% +$258K 0.01% 1405
2020
Q1 		$22.7M Buy
781,982
+474,058
+154% +$14.7M 0.01% 1309
2019
Q4 		$10.8M Buy
307,924
+9,033
+3% +$250K ﹤0.01% 2126
2019
Q3 		$6.42M Buy
+298,891
New +$8.27M ﹤0.01% 2404

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Northern Trust's BBIO Position: Q2 2026 in Review

Northern Trust reduced its BridgeBio Pharma (BBIO) stake by 32% in Q2 2026, selling an estimated $31.1M and leaving 959,513 shares worth $71.5M. The position accounts for 0.01% of the portfolio, ranked #992.

Northern Trust first reported a position in BBIO in Q3 2019 and has held it in 28 quarters since. The position peaked at $104M in Q1 2026. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Northern Trust held 959,513 shares of BridgeBio Pharma worth $71.5M as of Q2 2026.
  • Northern Trust sold 444,129 BridgeBio Pharma shares in Q2 2026, an estimated $31.1M.
  • BridgeBio Pharma made up 0.01% of Northern Trust's portfolio in Q2 2026, its #992 holding.
  • Northern Trust first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 28 quarters since.
  • Northern Trust's BridgeBio Pharma position peaked at $104M in Q1 2026.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.